In contrast, CBR-5884 is an inhibitor of phosphoglycerate dehydrogenase, blocking de novo serine synthesis in cells, and is selectively toxic to cancer cell lines with high serine biosynthetic activity against melanoma and breast cancer lines (56). This evidence concerns the gene PHGDH and breast carcinoma.